Ignite Creation Date:
2025-12-24 @ 9:30 PM
Ignite Modification Date:
2026-02-22 @ 9:36 AM
Study NCT ID:
NCT02704832
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-11-19
First Post:
2016-02-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}, {'id': 'D015179', 'term': 'Colorectal Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D011471', 'term': 'Prostatic Neoplasms'}, {'id': 'D001749', 'term': 'Urinary Bladder Neoplasms'}, {'id': 'D010051', 'term': 'Ovarian Neoplasms'}, {'id': 'D008223', 'term': 'Lymphoma'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D012002', 'term': 'Rectal Diseases'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D005834', 'term': 'Genital Neoplasms, Male'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D011469', 'term': 'Prostatic Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D014571', 'term': 'Urologic Neoplasms'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D001745', 'term': 'Urinary Bladder Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D004701', 'term': 'Endocrine Gland Neoplasms'}, {'id': 'D010049', 'term': 'Ovarian Diseases'}, {'id': 'D000291', 'term': 'Adnexal Diseases'}, {'id': 'D005831', 'term': 'Genital Diseases, Female'}, {'id': 'D005833', 'term': 'Genital Neoplasms, Female'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D006058', 'term': 'Gonadal Disorders'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'OTHER', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 792}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2016-09-30', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-11', 'completionDateStruct': {'date': '2026-03', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-11-15', 'studyFirstSubmitDate': '2016-02-19', 'studyFirstSubmitQcDate': '2016-03-05', 'lastUpdatePostDateStruct': {'date': '2024-11-19', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2016-03-10', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2023-12-31', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Overall survival defined as the delay between randomization and death, all causes.', 'timeFrame': 'Year 1'}, {'measure': 'Health related quality of life (HR-QoL) assessed using 3 scales of European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire.', 'timeFrame': 'Year 1'}], 'secondaryOutcomes': [{'measure': 'Overall survival defined as the delay between randomization and death, all causes.', 'timeFrame': 'Year 3'}, {'measure': 'Health related quality of life (hRQoL) assessed using 3 scales of EORTC QLQ-C30 questionnaire.', 'timeFrame': 'Year 3'}, {'measure': '6-month response rates defined as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 or Cheson criteria.', 'timeFrame': 'Month 6'}, {'measure': 'Toxicity graded according to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.', 'timeFrame': 'up to 3 years'}, {'measure': 'Number of unscheduled hospitalizations.', 'timeFrame': 'up to 3 years'}, {'measure': 'Length of unscheduled hospitalizations.', 'timeFrame': 'up to 3 years'}, {'measure': 'For the experimental arm only: Assessment of autonomy using Activities of Daily Living (ADL) questionnaire.', 'timeFrame': 'Months 0, 6, 12'}, {'measure': 'For the experimental arm only: Assessment of autonomy using Instrumental Activities of Daily Living (IADL) questionnaire.', 'timeFrame': 'Months 0, 6, 12'}, {'measure': 'For the experimental arm only: Assessment of depression using Geriatric Depression Scale (GDS-15) scale.', 'timeFrame': 'Months 0, 6, 12'}, {'measure': 'For the experimental arm only: Assessment of cognitive functions using mini mental state exam (MMSE).', 'timeFrame': 'Months 0, 6, 12'}, {'measure': 'For the experimental arm only: Assessment of comorbidities using Cumulative Illness Rating Scale for Geriatrics (CIRS-G) scale.', 'timeFrame': 'Months 0, 6, 12'}, {'measure': 'For the experimental arm only: Assessment of nutritional status using mini nutritional assessment (MNA) scale.', 'timeFrame': 'Months 0, 6, 12'}, {'measure': 'For the experimental arm only: Assessment of mobility using get-up and Go test.', 'timeFrame': 'Months 0, 6, 12'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Geriatric oncology', 'Intervention', 'Case management'], 'conditions': ['Breast Cancer', 'Colorectal Cancer', 'Lung Cancer', 'Prostate Cancer', 'Bladder Cancer', 'Ovarian Cancer', 'Lymphoma']}, 'referencesModule': {'references': [{'pmid': '27908282', 'type': 'DERIVED', 'citation': 'Soubeyran P, Terret C, Bellera C, Bonnetain F, Jean OS, Galvin A, Chakiba C, Zwolakowski MD, Mathoulin-Pelissier S, Rainfray M. Role of geriatric intervention in the treatment of older patients with cancer: rationale and design of a phase III multicenter trial. BMC Cancer. 2016 Dec 1;16(1):932. doi: 10.1186/s12885-016-2927-4.'}]}, 'descriptionModule': {'briefSummary': 'Randomized trials have already demonstrated that geriatric intervention was able to improve survival in the general elderly population but only a few have been performed in cancer patients. At the end, these data are not sufficient to consider geriatric intervention as validated in this setting. Case Management, coordinated by a geriatrician and a trained nurse, could improve prognosis of elderly patients with cancer. This approach, can be integrated in daily oncology practice. This strategy will be compared to usual oncological management in a randomized phase III trial.', 'detailedDescription': 'Patients will first be screened using the G8 screening tool. If the resulting score is altered (G8 \\<= 14), patients will be included in the main study and randomized according to 2 modalities: Arm A / Usual care (treatment according to on-going regimens in oncology) or Arm B /Case management (assessment of the patient by the nurse and the geriatrician with interventions as prescribed by the geriatrician). The intervention will be considered effective if, at one year, compared to usual care there is a significant clinical improvement in overall survival (OS) without a significant deterioration or/and clinical improvement of at least one of the targeted quality of life (QoL) scores, without significant clinical deterioration in at least one of the targeted QoL scores and without significant difference in OS in favor of usual care.\n\nIf the resulting score is normal (G8 \\> 14), patients will be treated according to their physician-in-charge opinion. A minimal set of data will be collected (age, sex, tumor type, disease stage, performance status (PS), creatinine clearance, albumin and C-Reactive Protein (CRP) levels mainly) to allow for the characterization of the population in order to compare our results to those of other published series.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['OLDER_ADULT'], 'minimumAge': '70 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Patient older 70 years and older\n2. Performance status 0 to 3 (WHO)\n3. G8 and QLQ-C30 questionnaires \'score are available\n4. No previous geriatric evaluation during cancer treatment\n5. Locally advanced or metastatic disease :\n\n 1. 1st line medical treatment :\n\n * Breast cancer : locally advanced or metastatic disease, hormone-resistant and Her2 negative,\n * Colon and rectum : metastatic (unresectable metastasis),\n * Prostate cancer : metastatic and refractory to hormonal castration,\n * Bladder cancer : locally advanced or metastatic,\n * Ovarian cancer : advanced stage (IIb to IV),\n * Lung cancer : metastatic non-small cell,\n * Lymphomas (indolent and aggressive)\n 2. Or 2nd line medical treatment :\n\n * Breast cancer : locally advanced or metastatic disease, hormone-resistant and Her2 negative,\n * Colon and rectum : metastatic (unresectable metastasis),\n * Prostate cancer : metastatic and refractory to hormonal castration,\n * Ovarian cancer : advanced stage (IIb to IV),\n * Lymphomas (indolent and aggressive)\n6. Life expectancy over 6 months\n7. Signed informed consent\n8. Patients with a French social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code).\n\nExclusion Criteria:\n\n1. Patient who already received 2 medical treatment lines\n2. Exclusive 1st or 2nd treatment lines of :\n\n * Hormonotherapy (except for prostate cancer : abiteratone acetate is allowed),\n * Surgery,\n * Radiotherapy,\n3. "Best supportive care" treatment\n4. Patient unable to understand quality of life questionnaire\n5. Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons.\n6. Patient placed under guardianship\n7. Planned concomitant participation to another medical interventional trial during the 12 months following the inclusion in the randomized study PREPARE\n8. Previous enrolment in the present study'}, 'identificationModule': {'nctId': 'NCT02704832', 'acronym': 'PREPARE', 'briefTitle': 'Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)', 'organization': {'class': 'OTHER', 'fullName': 'Institut Bergonié'}, 'officialTitle': 'Role of Geriatric Intervention in Treatment of Older Patients With Cancer : a Phase III Randomized Study (PREPARE)', 'orgStudyIdInfo': {'id': 'IB 2015-08'}, 'secondaryIdInfos': [{'id': 'ID-RCB number 2015-A01417-42', 'type': 'OTHER', 'domain': 'ANSM'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'NO_INTERVENTION', 'label': 'Arm A', 'description': 'Arm A "Standard oncological care": patients will be treated according to daily oncological practices as defined for each type of cancer, in the "Management protocol of Oncology" written and validated by a group of expert oncologists. The quality of life will be assessed every 3 months during the first year and at 18 months. The study\'s follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months.'}, {'type': 'EXPERIMENTAL', 'label': 'Arm B', 'description': 'Arm B "Geriatrician Intervention": patients will be treated according to the same "Management protocol of Oncology" than patients in the arm "Standard oncological care".\n\n* Before the beginning of the medical treatment, a comprehensive geriatric assessment will be performed by the geriatrician and the nurse that will define a plan of geriatric management care, according to the "Management protocol of Geriatrics".\n* The nurse, under the supervision of a geriatrician, will monitor implemented geriatric interventions. Phone follow-up will be performed every month for 6 months and at 9 months or during any change of situation according to a pre-established phone call plan. A full geriatric assessment by the geriatrician and the nurse will be performed at 6 and 12 months.', 'interventionNames': ['Other: Geriatrician Intervention']}], 'interventions': [{'name': 'Geriatrician Intervention', 'type': 'OTHER', 'description': "Arm B : The duration of the geriatric intervention will be 12 months. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months.", 'armGroupLabels': ['Arm B']}]}, 'contactsLocationsModule': {'locations': [{'zip': '38043', 'city': 'Grenoble', 'state': 'Auvergne-Rhône-Alpes', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire de Grenoble', 'geoPoint': {'lat': 45.17869, 'lon': 5.71479}}, {'city': 'Angers', 'country': 'France', 'facility': "Institut de Cancérologie de l'Ouest", 'geoPoint': {'lat': 47.47156, 'lon': -0.55202}}, {'zip': '60021', 'city': 'Beauvais', 'country': 'France', 'facility': 'Centre Hospitalier de Beauvais', 'geoPoint': {'lat': 49.43333, 'lon': 2.08333}}, {'zip': '62400', 'city': 'Béthune', 'country': 'France', 'facility': "Clinique Anne d'Artois", 'geoPoint': {'lat': 50.52965, 'lon': 2.64003}}, {'zip': '33076', 'city': 'Bordeaux', 'country': 'France', 'facility': 'Institut Bergonié Centre Régional de Lutte Contre le Cancer', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'zip': '33600', 'city': 'Bordeaux', 'country': 'France', 'facility': 'CHU de Bordeaux', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'zip': '14033', 'city': 'Caen', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire de Caen', 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}, {'zip': '69300', 'city': 'Caluire-et-Cuire', 'country': 'France', 'facility': 'Infirmerie Protestante de Lyon', 'geoPoint': {'lat': 45.79462, 'lon': 4.8464}}, {'zip': '81108', 'city': 'Castres', 'country': 'France', 'facility': 'Centre Hospitalier Intercommunal de Castres Mazamet', 'geoPoint': {'lat': 43.60527, 'lon': 2.24088}}, {'zip': '73011', 'city': 'Chambéry', 'country': 'France', 'facility': 'Centre Hospitalier Métropôle Savoie Chambéry', 'geoPoint': {'lat': 45.56628, 'lon': 5.92079}}, {'zip': '37500', 'city': 'Chinon', 'country': 'France', 'facility': 'Centre Hospitalier de Chinon', 'geoPoint': {'lat': 47.16701, 'lon': 0.24284}}, {'zip': '63000', 'city': 'Clermont-Ferrand', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire de Clermont-Ferrand', 'geoPoint': {'lat': 45.77969, 'lon': 3.08682}}, {'zip': '63011', 'city': 'Clermont-Ferrand', 'country': 'France', 'facility': 'Centre Jean Perrin', 'geoPoint': {'lat': 45.77969, 'lon': 3.08682}}, {'zip': '94000', 'city': 'Créteil', 'country': 'France', 'facility': 'AP-HP Henri Mondor', 'geoPoint': {'lat': 48.79266, 'lon': 2.46569}}, {'zip': '94010', 'city': 'Créteil', 'country': 'France', 'facility': 'Centre Hospitalier Intercommunal de Créteil', 'geoPoint': {'lat': 48.79266, 'lon': 2.46569}}, {'zip': '40107', 'city': 'Dax', 'country': 'France', 'facility': 'Centre Hospitalier de Dax', 'geoPoint': {'lat': 43.71032, 'lon': -1.05366}}, {'zip': '21079', 'city': 'Dijon', 'country': 'France', 'facility': 'Centre Georges François Leclerc', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}, {'zip': '97261', 'city': 'Fort de France', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire de Martinique'}, {'zip': '43000', 'city': 'Le Puy-en-Velay', 'country': 'France', 'facility': 'Centre Hospitalier Emile Roux', 'geoPoint': {'lat': 45.04366, 'lon': 3.88523}}, {'zip': '59037', 'city': 'Lille', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire de Lille', 'geoPoint': {'lat': 50.63391, 'lon': 3.05512}}, {'zip': '69003', 'city': 'Lyon', 'country': 'France', 'facility': 'Clinique Mutualiste Eugène André', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '69007', 'city': 'Lyon', 'country': 'France', 'facility': 'Hôpital Saint Joseph Saint Luc', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '69373', 'city': 'Lyon', 'country': 'France', 'facility': 'Centre Léon Bérard', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '13273', 'city': 'Marseille', 'country': 'France', 'facility': 'Institut Paoli Calmettes', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'zip': '40000', 'city': 'Mont-de-Marsan', 'country': 'France', 'facility': 'Centre Hospitalier de Mont de Marsan', 'geoPoint': {'lat': 43.89022, 'lon': -0.49713}}, {'zip': '34298', 'city': 'Montpellier', 'country': 'France', 'facility': 'Institut de Cancérologie de Montpellier', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'zip': '54519', 'city': 'Nancy', 'country': 'France', 'facility': 'Institut de Cancérologie de Lorraine', 'geoPoint': {'lat': 48.68439, 'lon': 6.18496}}, {'zip': '44202', 'city': 'Nantes', 'country': 'France', 'facility': 'Centre Catherine de Sienne', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'zip': '30029', 'city': 'Nîmes', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire de Nîmes', 'geoPoint': {'lat': 43.83665, 'lon': 4.35788}}, {'zip': '75010', 'city': 'Paris', 'country': 'France', 'facility': 'AP-HP Hôpital Saint Louis', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '64046', 'city': 'Pau', 'country': 'France', 'facility': 'Centre Hospitalier de Pau', 'geoPoint': {'lat': 43.31117, 'lon': -0.35583}}, {'zip': '24000', 'city': 'Périgueux', 'country': 'France', 'facility': 'Polyclinique Francheville', 'geoPoint': {'lat': 45.18691, 'lon': 0.71439}}, {'zip': '69495', 'city': 'Pierre-Bénite', 'country': 'France', 'facility': 'Hospices Civils de Lyon', 'geoPoint': {'lat': 45.70359, 'lon': 4.82424}}, {'zip': '22190', 'city': 'Pleurin Sur Mer', 'country': 'France', 'facility': 'Centre CARIO - HPCA'}, {'zip': '86000', 'city': 'Poitiers', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire de Poitiers', 'geoPoint': {'lat': 46.58261, 'lon': 0.34348}}, {'zip': '95300', 'city': 'Pontoise', 'country': 'France', 'facility': 'Centre Hospitalier René Dubos', 'geoPoint': {'lat': 49.05, 'lon': 2.1}}, {'zip': '74374', 'city': 'Pringy', 'country': 'France', 'facility': 'Centre Hospitalier Annecy Genevois', 'geoPoint': {'lat': 45.94622, 'lon': 6.12608}}, {'zip': '29107', 'city': 'Quimper', 'country': 'France', 'facility': 'Centre Hospitalier Intercommunal de Cornouaille', 'geoPoint': {'lat': 47.99597, 'lon': -4.09795}}, {'zip': '51726', 'city': 'Reims', 'country': 'France', 'facility': 'Centre Jean Godinot', 'geoPoint': {'lat': 49.26526, 'lon': 4.02853}}, {'zip': '35033', 'city': 'Rennes', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire de Rennes', 'geoPoint': {'lat': 48.11109, 'lon': -1.67431}}, {'zip': '35042', 'city': 'Rennes', 'country': 'France', 'facility': 'Centre Eugène Marquis', 'geoPoint': {'lat': 48.11109, 'lon': -1.67431}}, {'zip': '76031', 'city': 'Rouen', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire de Rouen', 'geoPoint': {'lat': 49.44313, 'lon': 1.09932}}, {'zip': '35760', 'city': 'Saint-Grégoire', 'country': 'France', 'facility': 'Centre Hospitalier Privé de Saint Grégoire', 'geoPoint': {'lat': 48.15101, 'lon': -1.68579}}, {'zip': '44800', 'city': 'Saint-Herblain', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire de Nantes', 'geoPoint': {'lat': 47.21154, 'lon': -1.651}}, {'zip': '60300', 'city': 'Senlis', 'country': 'France', 'facility': 'GHPSO Senlis Creil Picardie', 'geoPoint': {'lat': 49.20724, 'lon': 2.58661}}, {'zip': '35403', 'city': 'St-Malo', 'country': 'France', 'facility': 'Centre Hospitalier de Saint-Malo', 'geoPoint': {'lat': 48.64738, 'lon': -2.00877}}, {'zip': '67091', 'city': 'Strasbourg', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire de Strasbourg', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'zip': '31059', 'city': 'Toulouse', 'country': 'France', 'facility': 'Institut Claudius Regaud', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'zip': '59208', 'city': 'Tourcoing', 'country': 'France', 'facility': 'Centre Hospitalier de Tourcoing', 'geoPoint': {'lat': 50.72391, 'lon': 3.16117}}, {'zip': '37170', 'city': 'Tours', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire de Tours', 'geoPoint': {'lat': 47.39484, 'lon': 0.70398}}], 'overallOfficials': [{'name': 'Pierre-Louis SOUBEYRAN, PU-PH', 'role': 'STUDY_CHAIR', 'affiliation': 'Institut Bergonié'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Institut Bergonié', 'class': 'OTHER'}, 'collaborators': [{'name': 'Ministry of Health, France', 'class': 'OTHER_GOV'}], 'responsibleParty': {'type': 'SPONSOR'}}}}